Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in relapsed/refractory chronic lymphocytic leukemia and Richter's syndrome
NL-OMON58789Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Nov 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Richter's syndrome (RS) and diffuse large B-cell lymphoma (DLBCL) (7 arms), sponsored by Genmab. Started Nov 2020; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Richter's syndrome (RS)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON58789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58789.